1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Pandemic Still Putting Pressure On Novartis Oncology Portfolio

CEO Concerned About Diagnosis Delays

 
• By Kevin Grogan

As Vas Narasimhan spoke about his worries of missed diagnoses and worse outcomes, Q1 sales at the Swiss major's cancer business remained flat as new patient starts, physician visits and cancer screenings declined due to COVID-19.

COVID-19 shadow hanging over Novartis cancer drug sales • Source: Archive

Novartis AG has highlighted concerns about the delay in cancer diagnoses due to the COVID-19 pandemic and the impact it has had on the Swiss major's oncology business in the first quarter of 2021.

Speaking as Novartis posted total turnover of $12.41bn, down 2% at constant currencies, which included $3

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

China Biopharma Podcast - 14 May 2025 (Chinese Language)

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.